相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome
Matthew S. Davids et al.
BLOOD (2022)
Serum phosphate level and its kinetic as an early marker of acute kidney injury in tumor lysis syndrome
Marie Lemerle et al.
JOURNAL OF NEPHROLOGY (2022)
Tumor lysis syndrome, acute kidney injury and disease-free survival in critically ill patients requiring urgent chemotherapy
Moustafa Abdel-Nabey et al.
ANNALS OF INTENSIVE CARE (2022)
Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax
Stacy Diao et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial
Moritz Fuerstenau et al.
BLOOD (2021)
Tumor lysis syndrome risk in outpatient versus inpatient administration of venetoclax and hypomethlators for acute myeloid leukemia
Ari Pelcovits et al.
SUPPORTIVE CARE IN CANCER (2021)
Fluid overload and acute kidney injury in children with tumor lysis syndrome
Kayla Flood et al.
PEDIATRIC BLOOD & CANCER (2021)
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
William G. Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Arrhythmia in tumor lysis syndrome and associated in-hospital mortality: A nationwide inpatient analysis
Kishorbhai Gangani et al.
JOURNAL OF ARRHYTHMIA (2021)
Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax
Yu-Wen Wang et al.
ANNALS OF HEMATOLOGY (2020)
Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study
Seth E. Karol et al.
LANCET ONCOLOGY (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The epidemiology of rasburicase use in paediatric patients with acute lymphoblastic leukaemia and non-Hodgkin lymphoma
Rebecca Citrin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice
Lindsey E. Roeker et al.
CLINICAL CANCER RESEARCH (2019)
Ibrutinib and Venetoclax for First-Line Treatment of CLL
Nitin Jain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Rational use of rasburicase for the treatment and management of tumor lysis syndrome
Suhail A. Shaikh et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2018)
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cytokine release syndrome
Alexander Shimabukuro-Vornhagen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
The optimal single-dose regimen of rasburicase for management of tumour lysis syndrome in children and adults: a systematic review and meta-analysis
X. Yu et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2017)
A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome
Mitchell S. Cairo et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology
Gail L. Jones et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report
Paul J. Galardy et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Reanimation Respiratoire et Onco-Hematologique
Michael Darmon et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
The Tumor Lysis Syndrome
Scott C. Howard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus
Mitchell S. Cairo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Management of Hyperleukocytosis and Prevention of Tumor Lysis Syndrome with Low-Dose Prednisone Continuous Infusion in Children with Acute Lymphoblastic Leukemia
Mehmet Akif Ozdemir et al.
ACTA HAEMATOLOGICA (2009)
SYSTEMIC INFLAMMATORY RESPONSE SYNDROME AND MULTIPLE ORGAN DYSFUNCTION IN PATIENTS WITH ACUTE TUMOR LYSIS SYNDROME
Marcio Soares et al.
CLINICS (2009)
A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function
Mariano Malaguarnera et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome
Michiko Shimada et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review
Bertrand Coiffier et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents
Mitchell S. Cairo et al.
BLOOD (2007)
Acute renal failure from xanthine nephropathy during management of acute leukemia
Christopher LaRosa et al.
PEDIATRIC NEPHROLOGY (2007)
Tumour lysis syndrome: new therapeutic strategies and classification
MS Cairo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis
SC Goldman et al.
BLOOD (2001)
分享论文
